Related Experiment Video
Updated: Dec 13, 2025
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.9K
Targeting CD39 in cancer
Achim K Moesta1, Xian-Yang Li2, Mark J Smyth3
1Tizona Therapeutics, San Francisco, CA, USA.
Nature Reviews. Immunology
|July 31, 2020
Summary
Targeting CD39 (an enzyme crucial for adenosine production) shows promise in cancer immunotherapy. Inhibiting CD39 not only reduces immunosuppressive adenosine but also stabilizes pro-inflammatory ATP, restoring anti-tumor immunity.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- The ATP-adenosine pathway is a critical regulator of the tumor microenvironment's immune response.
- CD73 antagonists and A2A receptor inhibitors show therapeutic potential in cancer treatment.
- CD39 is the rate-limiting enzyme in converting ATP to adenosine, and its inhibitors are entering clinical trials.
Purpose of the Study:
- To review the impact of CD39 on innate and adaptive immunity in cancer.
- To discuss how CD39 inhibition affects the tumor microenvironment.
- To explore CD39-targeted immunotherapies and combination strategies.
Main Methods:
- Review of current literature on CD39 function in cancer immunity.
- Analysis of clinical data regarding CD73 and A2A receptor inhibitors.
- Discussion of emerging CD39 inhibitor clinical trial data.
Main Results:
- CD39 antagonism prevents adenosine accumulation and stabilizes extracellular ATP.
- CD39 inhibition restores anti-tumor immunity by modulating the tumor microenvironment.
- CD39 plays a significant role in both innate and adaptive immune responses within tumors.
Conclusions:
- CD39 antagonism offers a novel therapeutic strategy for cancer immunotherapy.
- Targeting CD39 can enhance anti-tumor immunity through multiple mechanisms.
- Combination therapies involving CD39 inhibitors hold significant promise for cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K
02:50Combination Therapies and Personalized Medicine
5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K